Loading data for TXMD — first visit, this takes a few seconds.
TherapeuticsMD Inc. (TXMD)
NasdaqGS: TXMD
· Real-Time Price · USD
2.08
+0.00 (0.00%)
At close: Aug 13, 2026, 8:00 PM
TherapeuticsMD Inc. (TXMD) Stock Price, Analysis & Data
0.00% (1D)
No data available
| Bid | 1.76 |
| Market Cap | 24.07M |
| Revenue (ttm) | 3.35M |
| Net Income (ttm) | 86K |
| Beta | 0.64 |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | n/a |
| Forward PE | 5.94 |
| P/B (ttm) | 0.89 |
| P/S (ttm) | 7.18 |
| Earnings Date | n/a |
| Ask | 2.4 |
| Volume | 6,913 |
| Avg. Volume (20D) | 37,148 |
| Open | 2.07 |
| Previous Close | 2.08 |
| Day's Range | 2.07 - 2.09 |
| 52-Week Range | 0.99 - 2.95 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About TXMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription p...
Sector Healthcare
IPO Date May 9, 2007
Employees 1
Stock Exchange NasdaqGS
Ticker Symbol TXMD
Website https://www.therapeuticsmd.com
Financial Performance
In 2025, TherapeuticsMD's revenue was 3.02M, an increase of 71.61% compared to the previous year's 1.76M. Earnings were -569K, a decrease of -73.91%.
Financial StatementsEarnings Surprise
TherapeuticsMD has released their quarterly earnings on Aug 14, 2023:
9 months ago · Associated Press Finance
TherapeuticsMD: Q3 Earnings SnapshotBOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Wednesday reported earnings of $152,000 in its third quarter.